Atypical Hyaline Vascular-Type Castleman's Disease With Thrombocytopenia, Anasarca, Fever, and Systemic Lymphadenopathy
Open Access
- 1 January 2013
- journal article
- case report
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of Clinical and Experimental Hematopathology
- Vol. 53 (1) , 87-93
Abstract
Recently, atypical Castleman's disease (CD) was reported in Japan. This disease is considered as TAFRO syndrome or non-idiopathic plasmacytic lymphadenopathy (IPL), a constellation of clinical symptoms, namely, thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly without hyper-γ-globulinemia. Histopathologically, this disease is similar to hyaline vascular (HV)-type CD. Here, we present a 43-year-old Japanese woman meeting the clinical criteria of TAFRO syndrome who was successfully treated with combined corticosteroid therapy. She showed a rapidly progressive course of thrombocytopenia, systemic lymphadenopathy, fever, anasarca, and increase in acute inflammatory proteins without hyper-γ-globulinemia. Lymph node biopsy was performed and revealed HV-type CD without human herpes virus 8 infection, which was clinicopathologically compatible with non-IPL. The association of these atypical features with well-known multicentric Castleman's disease (MCD), namely, HV-type histology with systemic lymphadenopathy, marked thrombocytopenia even with a high level of interleukin-6, and increased acute inflammatory proteins without hyper-γ-globulinemia, suggests that TAFRO syndrome as presented in our case is a novel entity, which may have been diagnosed as MCD in the past. To define this novel entity more clearly and to demonstrate its etiology, further nationwide surveys of this syndrome and MCD are needed. [J Clin Exp Hematopathol 53(1) : 87-93, 2013]Keywords
This publication has 26 references indexed in Scilit:
- Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory DiseasesInternational Journal of Biological Sciences, 2012
- Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximabEuropean Journal of Haematology, 2005
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomenaAmerican Journal of Hematology, 2005
- Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytesBlood, 2004
- A case of rheumatoid pericarditis with high concentrations of interleukin-6 in pericardial fluidHeart, 2000
- Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's diseaseBritish Journal of Haematology, 1999
- Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids.Journal of Clinical Investigation, 1996
- Interleukin 6 Induces the Expression of Vascular Endothelial Growth FactorJournal of Biological Chemistry, 1996
- Elevated levels of interleukin‐6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system invol vementArthritis & Rheumatism, 1990